Electronic Common Technical Document (eCTD): Structure, Submission Process, and Regulatory Updates
Abstract
The Electronic Common Technical Document (eCTD) has become a cornerstone in modern pharmaceutical regulatory submissions, offering a standardized, modular, and digital framework for dossier preparation and review. By integrating structured modules, XML backbone files, hyperlinks, and lifecycle management features, eCTD enhances efficiency, traceability, and compliance across multiple regulatory authorities. This review provides a comprehensive overview of eCTD, detailing its structure, submission process, regional variations, and recent regulatory updates, including the adoption of eCTD v4.0. The manuscript also examines practical insights from industry case studies, highlighting successful global submissions and lessons learned for post-approval lifecycle management. Challenges associated with eCTD implementation, such as technical complexities, regional disparities, data integrity concerns, and operational constraints, are critically discussed. Emerging trends, including artificial intelligence, automation, cloud-based platforms, and blockchain technology, are explored for their potential to improve submission accuracy, reduce review timelines, and enhance regulatory predictability. The review emphasizes the strategic role of eCTD not only as a compliance tool but also as a driver of efficiency, global harmonization, and informed decision-making in regulatory affairs. Understanding these aspects is essential for regulatory professionals, enabling optimized submission workflows and improved management of the pharmaceutical product lifecycle. Overall, eCTD has evolved from a regulatory submission format into a strategic enabler of efficiency, transparency, and global harmonization. Continued adoption of advanced digital technologies will further strengthen lifecycle management and regulatory decision-making.
Conclusion: Overall, eCTD has evolved from a regulatory submission format into a strategic enabler of efficiency, transparency, and global harmonization. Continued adoption of advanced digital technologies will further strengthen lifecycle management and regulatory decision-making.
Downloads
References
doi:10.1208/s12248-024-01002-w
2. Bishnoi M, Sonker A. Emergency use authorization of medicines: History and ethical dilemma. Perspect Clin Res [Internet]. 2023 Apr-Jun [cited 2026 Feb 18];14(2):49-55. Available from:
doi:10.4103/picr.picr_149_22
3. Collier R, Singh A, Chopra S. Harnessing AI/ML in drug and biological products discovery and development: The regulatory perspective. Pharmaceuticals (Basel) [Internet]. 2025 Jan [cited 2026 Feb 18];18(1):47. Available from: doi:10.3390/ph18010047
4. Di Bello F, Russo E, Sartori M. Enhancing regulatory affairs in the market placing of new medical devices: How LLMs like ChatGPT may support and simplify processes. AboutOpen [Internet]. 2024 [cited 2026 Feb 18];11(1):77-88. Available from:
doi:10.33393/ao.2024.3302
5. Dawar V, Sharma A, Mittal V, Sharma D. Global harmonization in drug approval: Bridging regulatory and clinical trial diversity. Curr Indian Sci.2024;2(3).
6. Liu Q, Huang R, Hsieh J, Zhu H, Tiwari M, Liu G, et al. Landscape analysis of the application of artificial intelligence and machine learning in regulatory submissions for drug development from 2016 to 2021. Clin Pharmacol Ther [Internet]. 2023 Apr [cited 2026 Feb 18];113(4):771-774. Available from:
doi:10.1002/cpt.2668
7. Niazi SK, Al-Shaqha WM, Mirza Z. Proposal of International Council for Harmonization guideline for the approval of biosimilars. J Mark Access Health Policy [Internet]. 2022 [cited 2026 Feb 18];11(1). Available from: doi:10.1080/20016689.2022.2147286
8. Pantanowitz L, Hanna M, Pantanowitz J, Lennerz J, Henricks WH, Shen P, et al. Regulatory aspects of artificial intelligence and machine learning. Arch Pathol Lab Med [Internet]. 2024 Oct [cited 2026 Feb 18];148(10):1185-1194. Available from:
doi:10.5858/arpa.2023-0123-RA
9. Suresh V, Kumar KS. Approval and marketing of medical products in EU, USA, India and Australia. Asian J Med Pharm Sci [Internet]. 2023 [cited 2026 Feb 18];11(1):73-82. Available from:
doi:10.30904/j.ajmps.2023.4619
10. Sireesha B, Haritha S, Lakshmi Thriveni S, Nikitha P, Vijaya Lakshmi UVS. Regulatory affairs and regulatory requirements for new drug approval. Int J Health Care Biol Sci [Internet]. 2024 [cited 2026 Feb 18];5(4):22-28. Available from:
doi:10.46795/ijhcbs.v5i4.643
11. Salunkhe P, Nagrale S. Electronic Common Technical Document (eCTD): Structure, Submission Process, and Regulatory Updates. Int J Drug Reg Affairs [Internet]. 2026Mar.13 [cited 2026 Feb.18];14(1):42-0. Available from: https://www.ijdra.com/index.php/journal/article/view/854
12. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH harmonised tripartite guideline: Common Technical Document for the registration of pharmaceuticals for human use (M4) [Internet]. Geneva: ICH; 2000 [cited 2026 Feb 18]. Available from:
https://www.ich.org/page/ctd
13. Food and Drug Administration. Providing regulatory submissions in electronic format-certain human pharmaceutical product applications and related submissions using eCTD specifications [Internet]. Silver Spring (MD): US FDA; 2023 [cited 2026 Feb 18]. Available from:
https://www.fda.gov
14. European Medicines Agency. Guideline on the electronic Common Technical Document (eCTD) v4.0 implementation [Internet]. Amsterdam: European Medicines Agency; 2022 [cited 2026 Feb 18]. Available from:
https://www.ema.europa.eu
15. Leligkou HC, Gerogiannis VC. Deep transformers for predicting ALCOA+ data integrity compliance. Appl Sci [Internet]. 2023 [cited 2026 Feb 18];13(13):7616. Available from:
doi:10.3390/app13137616
16. Central Drugs Standard Control Organization. Guidance for industry: Submission of applications in eCTD format [Internet]. New Delhi: CDSCO; 2024 [cited 2026 Feb 18]. Available from:
https://cdsco.gov.in
17. Pharmaceuticals and Medical Devices Agency. Technical specifications for eCTD v4.0 in Japan [Internet]. Tokyo: PMDA; 2023 [cited 2026 Feb 18]. Available from:
https://www.pmda.go.jp
18. Kumar R, Singh P. Transitioning from paper to eCTD: A roadmap for pharmaceutical SMEs in emerging markets. Regul Rapporteur.2024;21(4):12-18.
19. Zhang L, Miller J. Role of regulatory information management systems in global eCTD lifecycle management. J Pharm Compliance. 2025;9(2):45-59.
20. Brown S. Impact of XML-based backbones on regulatory review efficiency. Digit Med Regul Sci. 2024;6(1):101-114.
21. Beninger P. Signal management in pharmacovigilance. Clin Ther [Internet]. 2020 Jun [cited 2026 Feb 18];42(6):1110-1129. Available from:
doi:10.1016/j.clinthera.2020.03.018
22. Craveiro NS, Lopes BS, Tomás L, Almeida SF. Drug withdrawal due to safety. Curr Drug Saf [Internet]. 2020 [cited 2026 Feb 18];15(1):4-12. Available from:
doi:10.2174/1574886314666191004092520
23. Gozzo L. Pharmacovigilance and appropriate drug use. Healthcare (Basel) [Internet]. 2024 [cited 2026 Feb 18];12(6):669. Available from:
doi:10.3390/healthcare12060669
24. Holm JEJ, Ruppert JG, Ramsden SD. Impact of changing regulations on European risk management plans. Pharm Med [Internet]. 2022 Feb [cited 2026 Feb 18];36(1):33-46. Available from:
doi:10.1007/s40290-021-00414-8
25. Kandukuri A, Edla DR. Ensuring data safety in pharmacovigilance. Asian J Pharm Res Dev [Internet]. 2025 [cited 2026 Feb 18];13(3):1569. Available from:
doi:10.22270/ajprd.v13i3.1569
26. Khan MAA, Hamid S, Khan SA, Sarfraz M, Babar ZUD. Stakeholders’ views on pharmacovigilance in Pakistan. Front Pharmacol [Internet]. 2022 [cited 2026 Feb 18];13:891954. Available from:
doi:10.3389/fphar.2022.891954
27. Kiguba R, Olsson S, Waitt C. Pharmacovigilance in low- and middle-income countries. Br J Clin Pharmacol [Internet]. 2023 Feb [cited 2026 Feb 18];89(2):491-509. Available from:
doi:10.1111/bcp.15193
28. Lucas S, Ailani J, Smith TR, Abdrabboh A, Xue F, Navetta MS. Pharmacovigilance reporting requirements. Ther Adv Drug Saf [Internet]. 2022 [cited 2026 Feb 18];13. Available from:
doi:10.1177/20420986221125006
29. Pozsgai K, Szűcs G, Kőnig-Péter A, Balázs O, Vajda P, Botz L, et al. ADR reports related to substandard medical products. Front Pharmacol [Internet]. 2022 [cited 2026 Feb 18];13:964399. Available from:
doi:10.3389/fphar.2022.964399
30. Rewale KS, Tuwar AB, Salve MT. Brief review on pharmacovigilance. Int J Pharm Sci Drug Anal. 2024;4(1):9-16.
31. Robinson F, Wilkes S, Schaefer N, Goldstein M, Rice M, Gray J, et al. Patient-centered pharmacovigilance. Ther Adv Drug Saf [Internet]. 2023 [cited 2026 Feb 18];14. Available from:
doi:10.1177/20420986221146418
32. Sardella M, Belcher G, Lungu C, Ignoni T, Camisa M, Stenver DI, et al. Monitoring manufacturing quality of medicines. Ther Adv Drug Saf [Internet]. 2021 [cited 2026 Feb 18];12. Available from:
doi:10.1177/20420986211038436
33. Singh A, Kumar A. Pharmacovigilance in cell and gene therapy. Drug Saf [Internet]. 2025 [cited 2026 Feb 18]. Available from:
doi:10.1007/s40264-025-01596-9
34. CDSCO alerts: Retrospective analysis of quality control alerts (2018–2023). Regul Toxicol Pharmacol. 2025;156:105775.
doi:10.1016/j.yrtph.2025.105775.
35. Alemayehu C, Mitchell G, Nikles J. Barriers to clinical trials in developing countries. Int J Equity Health [Internet]. 2018 [cited 2026 Feb 18];17:37. Available from:
doi:10.1186/s12939-018-0748-6
36. Dirks A, Florez M, Torche F, Young S, Slizgi B, Getz K. Risk-based quality management in clinical trials. Ther Innov Regul Sci [Internet]. 2024 [cited 2026 Feb 18];58:520-527. Available from:
doi:10.1007/s43441-024-00618-5
37. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH E6(R3) Good Clinical Practice guideline [Internet]. Geneva: ICH; 2025 [cited 2026 Feb 18]. Available from: https://www.ich.org
38. Ridha A, Hussein S, AlJabban A, Gunay LM, Gorial FI, Al Ani NA. Clinical impact of seropositivity in RA patients. Open Access Rheumatol [Internet]. 2022 [cited 2026 Feb 18];14:113-121. Available from:
doi:10.2147/OARRR.S368190
39. Smolen JS, Landewé RB, Bijlsma JW, et al. EULAR recommendations for rheumatoid arthritis. Ann Rheum Dis [Internet]. 2020 Jun [cited 2026 Feb 18];79(6):685-699. Available from:
doi:10.1136/annrheumdis-2019-216655
40. Gabriel SE, Michaud K. Epidemiology of rheumatic diseases. Arthritis Res Ther [Internet]. 2009 [cited 2026 Feb 18];11(3):1-16. Available from:
doi:10.1186/ar2669
41. Murali K, Kaur S, Prakash A, Medhi B. Artificial intelligence in pharmacovigilance. Indian J Pharmacol [Internet]. 2019 Nov-Dec [cited 2026 Feb 18];51(6):373-376. Available from:
doi:10.4103/ijp.IJP_814_19
42. Rahman MS, Rahman MK, Kaykobad M, Rahman MS. Interpreting AI models using LIME and SHAP. Brain Inform [Internet]. 2024 [cited 2026 Feb 18];11(1):4. Available from:
doi:10.1186/s40708-024-00213-9
43. Santoro A, Genov G, Spooner A, Raine J, Arlett P. EU pharmacovigilance system. Drug Saf [Internet]. 2017 Oct [cited 2026 Feb 18];40(10):855-869. Available from:
doi:10.1007/s40264-017-0572-8
44. Silva MR, Santos LK, Oliveira PJ, et al. AI in Brazilian pharmaceutical regulation. Regul Sci Med Prod. 2024;14:189-198.
45. Yaeger KA, Martini M, Rasooly J, Samir AE, Louissaint A.AI-based image analysis in cytopathology. Cytopathology [Internet]. 2019 Oct [cited 2026 Feb 18];30(5):489-497. Available from:
doi:10.1111/cyt.12728
46. Harmark L, van Grootheest AC. Pharmacovigilance: Methods and perspectives. Eur J Clin Pharmacol [Internet]. 2008 Aug [cited 2026 Feb 18];64(8):743-752. Available from:
doi:10.1007/s00228-008-0475-9
47. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Q8–Q10 guidelines [Internet]. Geneva: ICH; 2009 [cited 2026 Feb 18]. Available from:
https://www.ich.org
48. Jeetu G, Anusha G. Pharmacovigilance worldwide. J Young Pharm [Internet]. 2010 Jul-Sep [cited 2026 Feb 18];2(3):315-320. Available from:
doi:10.4103/0975-1483.66802
49. Talbot JC, Nilsson BS. Pharmacovigilance in the pharmaceutical industry. Br J Clin Pharmacol [Internet]. 1998 May [cited 2026 Feb 18];45(5):427-431. Available from:
doi:10.1046/j.1365-2125.1998.00713.x
50. Trippe ZA, Brendani B, Meier C, Lewis D. Identification of substandard medicines using ICSR analysis. Drug Saf [Internet]. 2017 Apr [cited 2026 Feb 18];40(4):293-303. Available from:doi:10.1007/s40264-016-0499-5
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The International Journal of Drug Regulatory affairs require a formal written transfer of copyright from the author(s) for each article published. We therefore ask you to complete and return this form, retaining a copy for your records. Your cooperation is essential and appreciated. Any delay will result in a delay in publication.
I/we have read and agree with the terms and conditions stated Page 2 of this agreement and I/we hereby confirm the transfer of all copyrights in and relating to the above-named manuscript, in all forms and media, now or hereafter known, to the International Journal of Drug Regulatory affairs, effective from the date stated below. I/we acknowledge that the IJDRA is relying on this agreement in publishing the above-named manuscript. However, this agreement will be null and void if the manuscript is not published in the IJDRA.
Download link for COPYRIGHT FORM
